Searchable abstracts of presentations at key conferences in endocrinology

ea0029p537 | Diabetes | ICEECE2012

Relationship between serum levels of 1-84 parathormone (PTH1-84) and obesity, HOMA insulin-sensitivity or beta-cells function (HOMA-B) in type 2 diabetic patients

Belovici M. , Buysschaert M.

Introduction: PTHrP (Parathyroid hormone-related protein) is known to enhance beta cell function and proliferation. PTH levels predict myocardial and coronary heart disease in non-diabetic patients with normal calcium levels and no kidney failure. We aimed at determining in type 2 diabetes patients without kydney failure the relationship between serum levels of 1-84 parathormone (PTH1-84), obesity, HOMA insulin-sensitivity or beta-cells function (HOMA-B), but also between PTH1...

ea0029p883 | Endocrine tumours and neoplasia | ICEECE2012

Clinically palpable parathyroid adenoma

Kaushal M. , Nagar M.

A palpable parathyroid mass, in a patient with primary hyperparathyroidism, is presumed to be parathyroid carcinoma until proven otherwise, with other less common causes including parathyroid cysts and adenomas.In developing world primary hyperparathyroidism presented in different way not only in the disease age group as well as in clinical symptoms and signs. More cases of symptomatic PHPT are presented in younger age group and some time large adenomas ...

ea0029p1757 | Thyroid cancer | ICEECE2012

Optimal prophylactic and definitive therapy for bicalutamide induced gynaecomastia: results of meta-analysis

Tunio M , Asiri M

Objective: Bicalutamide is approved as an adjuvant to primary treatments (radical prostatectomy or radiotherapy) or as monotherapy in men with locally advanced, nonmetastatic prostate cancer (PCa); however, this treatment induces gynaecomastia in most of patients, which results in treatment withdrawal. Optimal therapy for these breast events is not known so far. We conducted a meta-analysis to assess the efficacy of different treatment options for bicalutamide induced gynaecom...

ea0029p1774 | Thyroid cancer | ICEECE2012

Role of intensity modulated radiation therapy in patients with non-anaplastic thyroid carcinoma: king fahad medical city experience

Tunio M. , Asiri M.

Background: To evaluate outcomes and toxicities in patients with non-anaplastic thyroid cancer treated with intensity modulated radiation therapy (IMRT).Materials and methods: This was a single institution retrospective review of 18 patients with non-anaplastic thyroid cancer treated with IMRT at King Fahad Medical City between April 2005 and December 2010. The median age was 69 years. Among the 18 patients, fifteen had papillary carcinoma, two had T3 an...

ea0016me13 | (1) | ECE2008

Endocrine management of gonadal tissue conservation

Dolmans M M

Advances in the diagnosis and treatment of childhood, adolescent and adult cancer have greatly increased the life expectancy of young women with cancer, but have resulted in a growing population of adolescent and adult long-term survivors of childhood malignancies, who may experience premature ovarian failure (POF) and infertility as a result of aggressive chemotherapy and radiotherapy treatments (indicated for both cancer and bone marrow transplantation (BMT)).<p class="a...

ea0009p211 | Clinical | BES2005

Evolving tumour behaviour in a patient with combined Conn's and Cushing's syndrome

Forbes M , Daly M

In 1993 a 33-year old female was diagnosed biochemically with both Conn's and Cushing's syndrome. A large right-sided adrenal mass was found on CT scan of the abdomen and a right-sided adrenalectomy was performed. Histology reported a benign, 7 centimetre adrenocortical tumour, secreting both cortisol and aldosterone. Annual assessments of urinary cortisol and plasma aldosterone/renin ratios remained normal until September 2002, when she noticed a weight gain of 6 kilograms an...

ea0083pno3 | Pituitary and Neuroendocrinology | EYES2022

Development of novel immunoassays for the pro-opiomelanocortin joining peptide (A surrogate marker of adrenocorticotrophin levels) for use in the diagnosis of Cushing’s syndrome

M. Donnelly

Background: Excess adrenocorticotrophin (ACTH), most often from a pituitary tumour, results in the overproduction of cortisol and the condition, Cushing’s syndrome. Plasma ACTH measurements are used in the diagnosis of Cushing’s syndrome but due to the presence of multiple dibasic cleavage sites within its sequence, ACTH is extremely labile and far from an ideal analyte. Processing of ACTH by some ectopic tumours releases high levels of smaller-ACTH like fragments, &...

ea0035s8.3 | Membrane lipid composition and receptor function. Signalling and trafficking | ECE2014

Membrane dynamics in physiology and disease: PI3K signaling

Wymann M

Phosphoinositide 3-kinase γ (PI3Kγ) is key to inflammation, allergy, cardiovascular, and metabolic disease.1 PI3Kγ is a drug target in chronic inflammation, rheumatoid arthritis,2 atherosclerosis3 and allergic responses.4,5 Localized, PI3Kγ-mediated PtdIns (3,4,5)P3 production5, and a distinct role of Ras selectively activating the p84–PI3Kγ-complex, can modulate PI3Kγ...

ea0033en3 | Endocrine Nurse Programme | BSPED2013

Multiple endocrine neoplasia (MEN) an overview

Ahmed M

Multiple endocrine neoplasia type 1 (MEN1) and MEN) are distinct clinical and genetic entities.This talk will cover the key clinical features and surveillance strategies for each of these conditions....